EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

***katarzyna.kacprzak***

*23.06.2022, 11:52:20*

---------------------------------

Valid with addendum number 1 to the Project Contract 2018-1-0659

Valid with addendum number 1 to the Project Contract 2018-1-0659



**EEA and Norway Grants Fund for Regional Cooperation**

**Common Challenges – Shared Solutions**

**PROJECT DESCRIPTION**

**Project Index No.: 2018-1-0659**

**Project title : TBFVnet: surveillance and research on tick-borne flaviviruses (TBFV)**

**Lead partner : Veterinary Research Institute**

Fund operated by



*Page 1/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

**SECTION 1 - Project overview**

***1.1 General Information***

|  |  |
| --- | --- |
| Fund | EEA and Norway Grants Fund for Regional Cooperation |
| Fund priority sectors | Innovation, Research, Education and Competitiveness |
| Project title | TBFVnet: surveillance and research on tick-borne flaviviruses (TBFV) |
| Project index number | 2018-1-0659 |
| Name of the lead partner organisation (in English) | Veterinary Research Institute |
| Country of the lead partner organisation | Czech Republic |
| Estimated start date of implementation | 01/07/2020 |
| Estimated end date of implementation | 31/01/2024 |
| Project duration (in months) | 43 |
| Total estimated eligible Project costs (in EUR) | € 1.338.908,00 |
| Maximum requested grant amount (in EUR) | € 1.195.517,00 |

***1.2 Project summary***

*Please update the project summary. Provide a short description of your project idea with focus on goals and expected results. Make sure this section is well edited and presents your* *project in the most accurate and concise form. Make sure the following elements are covered:*

*the priority sector(s) and programme area(s) you are addressing in your project*

*relevance of project proposal in relation to the objective, principles and priorities of the call* *the expected change your project will make to the current situation*

*the direct target groups and the end beneficiaries of the project*

*the transnational added value of the project*

*the expected sustainability of the project beyond the end of the funding period*

**TBFVnet** identifies tick-borne flaviviruses (TBFVs) as a **research, health and social priority** requiring a **multidisciplinary and cross-border approach** in the target Region (areas of interest of the Fund). TBFVs include a large number of human and animal pathogens causing severe disease. Tick-borne encephalitis virus (TBEV), Powassan virus (POWV) and Louping-ill virus (LIV) cause encephalitis, while Omsk hemorrhagic fever virus (OHFV) is hemorrhagic. TBEV is considered the most relevant arbovirus in Central and Eastern Europe and in Russia, with about 13.000 estimated human cases annually. Over the last decade there has been a 300% increase in the number of TBE cases in Europe, and TBEV is currently spreading in France, Sweden, Norway and Italy. This expansion poses an increased risk for the population and for the workers engaged in outdoor activities. Among the patients that experience neuroinvasive TBEV infection, approximately 25–40% of the survivors suffer from long lasting neurological *sequelae*. There are currently no antivirals for the treatment of TBFV infections and a prophylactic vaccine is available only for TBEV. Moreover, the biology of the virus as well as the mechanisms of pathogenicity remain poorly understood and

*Page 2/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

there are no common surveillance and diagnosis strategies to monitor the spread and risk of exposure.

**TBFVnet** aims at creating a network of associated laboratories at two levels: as core alliance between **partners willing to share common tools and protocols**; and, subsequently, to **transfer best practices to neighboring countries**. A joint research platform to investigate the biology and pathogenesis of TBFV disease and to study novel antivirals and

prophylactic immunity will complement the action. It is expected that the integration of research and surveillance will create positive synergies for both fields.

Direct target groups are PPs staff and young researchers that will benefit from **collaborative basic research, development of innovative tools and bio-markers, exchange visits** to Expertise partners. Planned activities will lead to a **stable cross-border network able to tackle TBFV disease at all levels through reliable and comparable data**, and will contribute, in the long term, to the definition of a forecast tool for geographical distribution of TBFV. Public health and veterinary institutions, biotech companies and the population at large, will benefit from knowledge advancement and unlocked R&I potential.

**The partnership brings specific expertise**: the Lead Partner, based in the Czech Republic, at the heart of the endemic area in Central Europe, has a long-standing interest in TBEV pathogenesis and antivirals discovery; Slovakia deals with TBEV research and isolation as well as with the characterization of wild viral strains. Both partners are engaged in national surveillance programs and collaborate with diagnostic laboratories. As highly pathogenic strains of TBEV, as well as other TBFVs such as OHFV, originate from Russia representing a threat to Europe, the Chumakov Institute in Moscow has been strategically included. Expertise partners at the Northern borders complement the consortium: Norway having a wide knowledge of surveillance of TBFVs and LIV; Sweden is specialized in the molecular biology of TBEV infection. The ICGEB, an intergovernmental organization, will provide expertise in TBEV biology and diagnosis available at its labs in Trieste, at the Southern border of the endemic area in Western Europe, and an umbrella of institutional contacts in other ICGEB Members of the target Region.

The network will be promoted as **relevant forum for the exchange of data and research methods also after project completion**. Specific dissemination tools and events will be organized during and after the project to reach out to potential end beneficiaries and encourage uptake of project results. Cost-effective in-house solutions produced will remain with the PPs and reduce public costs for surveillance.

*Page 3/53*

EEA and Norway Grants Fund for Regional Cooperation   
PROJECT DESCRIPTION

**SECTION 2 - Partners**

|  |  |
| --- | --- |
| ***2.1 Lead partner*** | |
| Project partner number | 1 |
| Name of organisation in English | Veterinary Research Institute |
|  | Address |
| Country | Czech Republic |
| Postal address | Hudcova 70, CZ-62100 Brno, Czech Republic |
| Website | <https://www.vri.cz> |
|  | Legal information |
| Legal status | University or research institution |
| Type of identification number | VAT |
| Identification number | CZ00027162 |
| Legal representative name(s) | xxxxxxxxxxxxxxxxxxxx |
|  | Contact information |
| Contact person's name | xxxxxxxxxxxxxxxxxxxx |
| Contact person's e-mail address | xxxxxxxxxxxxxxxxx |
| Contact person's telephone number | xxxxxxxxxxxxxxxxxx |

|  |  |
| --- | --- |
| ***Beneficiary partner*** | |
| Project partner number | 2 |
| Name of organisation in English | Federal State Autonomous Scientific Institution «Chumakov Federal Scientific Center for Research and Development of Immune-and-biological Products of Russian Academy of Sciences» (Institute of Poliomyelitis) |
|  | Address |
| Country | Russia |
| Postal address | prem. 8, korp. 1, village Institute of poliomyelitis, poselenie Moskovskiy, 108819 Moscow, Russia |
| Website | <http://chumakovs.ru/> |
|  | Legal information |
| Legal status | University or research institution |
| Type of identification number | TIN/RRC 7751023847/775101001 |
| Identification number | OGRN 1167746624847 |

*Page 4/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |
| --- | --- |
| Legal representative name(s) | xxxxxxxxxxxxxxxxxxxxxxx |
|  | Contact information |
| Contact person's name | xxxxxxxxxxxxxxxxxxxxxx |
| Contact person's e-mail address | xxxxxxxxxxxxxxxxxxx |
| Contact person's telephone number | xxxxxxxxxxxxxxxxxxxx |

|  |  |
| --- | --- |
| ***Beneficiary partner*** | |
| Project partner number | 3 |
| Name of organisation in English | Biomedical Research Center of the Slovak Academy of Sciences |
|  | Address |
| Country | Slovakia |
| Postal address | Dúbravská cesta 9, 84505 Bratislava |
| Website | <http://www.bmc.sav.sk/> |
|  | Legal information |
| Legal status | University or research institution |
| Type of identification number | Registry No |
| Identification number | 50073869 |
| Legal representative name(s) | xxxxxxxxxxxxxxxxxxxxxxx |
|  | Contact information |
| Contact person's name | xxxxxxxxxxxxxxxxxxxxxx |
| Contact person's e-mail address | xxxxxxxxxxxxxxxxxxx |
| Contact person's telephone number | xxxxxxxxxxxxxxxxxxxx |

|  |  |
| --- | --- |
| ***Expertise partner*** | |
| Project partner number | 4 |
| Name of organisation in English | Norwegian Institute of Public Health |
|  | Address |
| Country | Norway |
| Postal address | PO Box 222 Skøyen, N-0213 Oslo, Norway |
| Website | <https://www.fhi.no/en/> |

*Page 5/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |
| --- | --- |
|  | Legal information |
| Legal status | Public |
| Type of identification number | Org. no. |
| Identification number | Org. no. 983 744 516 |
| Legal representative name(s) | xxxxxxxxxxxxxxxxxxxxxxxx |
|  | Contact information |
| Contact person's name | xxxxxxxxxxxxxxxxxxxxxxxxx |
| Contact person's e-mail address | xxxxxxxxxxxxxxxxxxxxxxxxxx |
| Contact person's telephone number | xxxxxxxxxxxxxxxxxxxxxxx |

|  |  |
| --- | --- |
| ***Expertise partner*** | |
| Project partner number | 5 |
| Name of organisation in English | Umeå University |
|  | Address |
| Country | Sweden |
| Postal address | SE-901 87 Umeå |
| Website | <http://www.umu.se/english/?languageId=1> |
|  | Legal information |
| Legal status | University or research institution |
| Type of identification number | VAT |
| Identification number | SE202100287401 |
| Legal representative name(s) | xxxxxxxxxxxxxxxxxxxxxxx |
|  | Contact information |
| Contact person's name | xxxxxxxxxxxxxxxxxxxxx |
| Contact person's e-mail address | xxxxxxxxxxxxxxxxxxxxxxx |
| Contact person's telephone number | xxxxxxxxxxxxxxxxxxxxxxxxx |

|  |  |
| --- | --- |
| ***Expertise partner*** | |
| Project partner number | 6 |
| Name of organisation in English | International Centre for Genetic Engineering and Biotechnology - ICGEB |

*Page 6/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |
| --- | --- |
|  | Address |
| Country | International |
| Postal address | Padriciano 99, 34149 Trieste, ITALY |
| Website | <http://www.icgeb.org/home.html> |
|  | Legal information |
| Legal status | International organisation |
| Type of identification number | Tax No |
| Identification number | 90031700322 |
| Legal representative name(s) | xxxxxxxxxxxxxxxxxxxxxxx |
|  | Contact information |
| Contact person's name | xxxxxxxxxxxxxxxxxxxxxxxxxx |
| Contact person's e-mail address | xxxxxxxxxxxxxxxxxxxxxxx |
| Contact person's telephone number | xxxxxxxxxxxxxxxxxxxxxxxxx |

*Page 7/53*

EEA and Norway Grants Fund for Regional Cooperation   
PROJECT DESCRIPTION

**SECTION 3 - Project description**

***3.1 Project objectives and expected outcomes***

**Project objective**

*What is the problem that the project is going to address? What are the needs of the target group(s) (end beneficiaries)? What is the project’s objective and how does it link to the* *Fund’s objective, principles and priorities, as outlined in the call for proposals?*

The objective of TBFVnet is to **establish a stable cross-country network that will provide innovative approaches for surveillance and research on tick-borne flaviviruses**, including TBEV, the most prevalent flavivirus in Central Europe. TBFVs include many pathogens causing severe human diseases, ranging from mild fever to encephalitis and hemorrhagic fever. TBFVs are endemic in the Region and, due to climate change, are rapidly expanding posing an increasing infectious threat in all Europe. The management of such diseases requires a high degree of transnational cooperation in different sectors: healthcare, research, veterinary and the environment.

Focusing on **Priority 1, PPs will pool and complement their specific expertise** by sharing and comparing data collected in different areas, exchanging knowledge and techniques, defining new research methods, thus improving their research performance and generating new solutions to the analysis and management of this major challenge.

TBFVnet specific aims and beneficiaries:

-to establish common tools and protocols for the diagnosis and surveillance of TBFVs - public health, veterinary centers

-to investigate the molecular correlates of pathogenesis of TBFVs - research community, ESRs

-to develop new antivirals - scientists/pharma industry

-to expand an international alliance to tackle TBFVs - PPs, the Region

**Project outcomes**

|  |  |
| --- | --- |
| **No** | **Name of the outcome** |
| 1 | Enhanced performance of research institutions |
| 2 | Enhanced cooperation and improved mutual knowledge and understanding between the  donor and beneficiary states. |

**Outcomes indicators**

**Outcome name Indicators Unit of measurement Baseline value Baseline year Target values**

*Page 8/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Enhanced performance of research institutions | Number of new products/technologies developed | number | 0,00 | 2019 | 2,00 |
| Number of registered applications for Intellectual Property Protection | number | 0,00 | 2019 | 1,00 |
| Number of articles submitted to peer-reviewed publications | number | 12,00 | 2019 | 32,00 |
| Common tools/protocols established | number | 0,00 | 2019 | 2,00 |
| Partners involved in the TBFV scientific network | number | 6,00 | 2019 | 8,00 |
| Joint articles submitted to peer-reviewed publications | number | 1,00 | 2019 | 8,00 |
| Joint applications for further funding | number | 0,00 | 2019 | 3,00 |
| Enhanced cooperation and improved mutual knowledge and understanding between the donor and beneficiary states. | Level of trust between cooperating entities in Beneficiary States and Donor  States | scale (1-7) | 0,00 | 2019 | 5,00 |
| Level of satisfaction with the partnership | scale (1-7) | 0,00 | 2019 | 5,00 |
| Share of cooperating organisations who apply the knowledge acquired from bilateral partnership | percentage | 0,00 | 2019 | 75,00 |

**Project outputs**

*Please give a general description of your project outputs, then define the specific outputs contributing to project outcomes*

It is expected that the realization of joint research studies on TBFVs surveillance and the definition of a common framework to investigate TBFVs will contribute to enhance the performance of partnering research institutions. Indeed, all PPs will benefit from data exchanges, collaborative research and comparative studies thus advancing the knowledge on TBFVs and increasing their internal expertise. Scientific meetings, reciprocal short visits and mobility of junior scientists will allow Beneficiary Partners to acquire new research techniques and increase multidisciplinary interaction. The formal establishment of a Regional TBFVnet through a dedicated website, annual conferences, joint publications and other

*Page 9/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

dissemination activities targeting the PPs and other institutions in neighboring countries, will further contribute to enhance the research capacity on TBFVs and to expand cooperation between the Donor and Beneficiary States on this common challenge.

|  |  |  |  |
| --- | --- | --- | --- |
| **Outcome Output title Output Description Due date**  Enhanced performance of research  institutions |  |  |  |
|  | Training on diagnostic assays delivered | The expected result is the establishment of shared tools and protocols among the project  consortium to allow for comparable diagnosis and surveillance of TBFVs in animals and humans. This will be reached through: exchange of research material and training sessions delivered by Expertise partners to Beneficiary partners, with particular  reference to serological and molecular tests; preparatory and subsequent experiments by each PP and comparison of results among the partnership. | 31/01/2024 |
| Cross-labs experiments for antiviral drug discovery conducted | The expected result is the definition of a common research framework to study TBFV pathogenesis with the ultimate goal of improving the response to TBFVs infections. This will be reached through exchange of junior staff among partners to conduct cross- labs experiments, in particular to implement models of TBFVs pathogenesis designed to test antiviral strategies. Molecular correlates of TBFV pathogenesis will be studied taking advantage of the expertise partners MIMS  and ICGEB. Models of tick-borne transmission, infection and tissue tropism will be available at VRI, CFSC and SAS. | 31/01/2024 |

*Page 10/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |
| --- | --- | --- | --- |
| Enhanced cooperation and improved mutual knowledge and understanding between the donor and beneficiary states. | Scientific interaction between Donor and Beneficiary States facilitated | It is expected that the 4-year collaboration will lead to the consolidation of a core network of research institutions from Donor and Beneficiary States collaborating on the surveillance and diagnostics of TBFVs. This will entail exchange of knowledge, expertise and personnel, collaborative research, joint publications and the organisation of, and participation in, dissemination events. Moreover, the ICGEB will make available its own network of Member Countries in the Region to approach key laboratories in TBFVs research and surveillance in order to enlarge the platform and allow for additional sharing of data, protocols and reagents key to further study the topic. All PPs will try to bring in other collaborations to expand the network. | 31/01/2024 |

**What is the project’s approach/method in addressing the challenges of the chosen support area(s)?**

*Please make sure to address the chosen support area or areas if the project concerns more than one. Describe the approach in detail and include references to the research/good* *practice/experiences it rests on. Include information on how to reach and work with the target group(s) and other stakeholders.*

Research within TBFVnet is at the clinical and veterinary level, with joint studies addressing viral pathogenicity. **Sharing and integration of protocols and tools among PPs** will be critical to uniform research results among different laboratories. **Short-term staff exchange between partners** will be also instrumental to forge the next generation of scientists in this **specific multidisciplinary approach**. Integration of surveillance data, definition of sentinel animals, development of careful mapping of disease prevalence on the territory and integration with climate change data provides the basis to predict seasonal risk areas in advance. Similarly, definition of markers of TBEV-induced encephalitis and development of antivirals are the prerequisites for the management of the complications of infection.

TBFVnet approach includes **joint research and capacity building in virus diagnostic and surveillance** including the collection of direct whole-genome sequences of wild TBFVs to establish a shared bio-bank of molecular clones, the investigation of the host antiviral response to TBFVs infection in the different animal and human host, the investigation of the mechanism of TBFV pathogenicity in vitro and in vivo, the discovery of new antivirals and vaccines. A training component will be implemented through workshops and short-term mobility schemes for junior staff to Expertise partners and other PPs laboratories, based on research needs.

**Dissemination and outreach activities** will be implemented both within TBFVnet partners and in neighboring endemic countries.

These approaches will contribute to the **establishment of a platform for the development of antivirals for TBFV diseases and to the development of molecular and serological**

*Page 11/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

**diagnostic tools** developed by the partners to provide shared **in-house tools for TBFVs** infection surveillance and management thus enhancing the research performance and capacity of the involved PPs.

Furthermore, joint collaborative research will **contribute to pave the way to the elaboration of web-based forecasting tool** that could, in the future, take advantage of the input of surveillance data from the Partners and associated laboratories to predict seasonal geographical distribution and risk of exposure.

***3.2 Project relevance***

**What are the European challenges to be addressed by the project?**

*Place your project within the context described in the call. Relate it to the challenges in the countries participating in the project. Please refer to relevant research/statistics/facts to* *support your text.*

TBFVnet is in line with the EEA and Norway Grants challenge of strengthening bilateral relations with 15 EU countries and reduce economic and social disparities in the EEA. It focuses on Priority 1 by **enhancing research-based knowledge** development in the specific field of tick borne diseases, including finding in-house detection tools that will **reduce the costs**

**for public health institutions**. TBFVnet will capitalize on the results of previous bilateral collaborations among PPs and with other potential beneficiaries in the Region. In the period 2012-2016, in the EU and in the EEA 12,500 cases of tick-borne encephalitis were observed: 2522 in Czech Republic, 638 in Slovakia, 1180 in Sweden and 47 in Norway 47 (Beauté et al. Eurosurveillance 2018).

TBFVnet is aligned with the **Europe2020 Strategy** for smart, sustainable and inclusive growth and with the EU cohesion policy objective of strengthening research, technological development and innovation. It is in line with **H2020 Societal Challenge 1 “Health, demographic change and wellbeing”** (and to a minor, yet relevant extent SC2 on food security and agriculture). TBFVnet has also the potential to contribute to the work of EIP AGRI and EIP on Active Healthy Ageing.

TBFVnet will contribute to the **Danube Region Strategy, in particular to priority area 7** "To develop the Knowledge Society (research, education and ICT)", and its targets of enhancing academic mobility and increasing the annual output of co-publications in the region. It will also contribute to the **EU Strategy for the Baltic Sea Region** in particular to create a **dynamic environment for research and innovation** by promoting dialogue and effective cooperation in Northern and Central Europe.

Overall, the initiative has the **potential to highly impact the R&I capacities of EU countries** and the cooperation intra-EEA and among beneficiary countries. In the long term, it will contribute to **improving public health care and coordination of surveillance systems**.

**Project partners may cooperate in one of two ways:**

1. **Regional cross-border cooperation** between eligible countries (regional focus) 2. **Transnational cooperation** between eligible countries

*Please explain why the project goals cannot be efficiently reached acting only on a national/regional/local level and/or describe what benefits the project partners/target groups/project* *area will gain in taking a transnational or regional cross-border approach. For projects with an expertise partner from a Donor State, please explain how the project will contribute to*

*Page 12/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

*strengthening the relations between the Donor State and the other countries in the project consortium.*

TBFVs infections are expanding East-West and to Northern and Southern Europe with a **patched distribution that depends on the diffusion of the vector and of the animal** **reservoirs**. A **high seasonal variability** has been observed making forecasts difficult without a constant and capillary surveillance. TBFVs are mainly tackled at the national/local level and **more cooperation among endemic regions is needed to better control and manage the prediction, transmission, detection, and treatment of these infections.**

**Beneficiary partners are at the core of the endemic area, while Expertise partners, where TBFVs are also endemic, provide surveillance and research tools open to the** **network**. The role of the ICGEB, besides its expertise in diagnostic and research, is instrumental to expand the activities of TBFVnet within its constituency overlapping with the target Region. PPs will be able to compare data from different areas, exchange knowledge and improve research capacity on this topic.

TBFVnet will contribute to strengthening the relations between the **Donor State Norway and the other countries**, as they **will collaborate in the joint definition of common** **strategies for TBFVs surveillance**. In particular, NIPH will share its experience in ticks collection in relation with climate conditions, cultivation of virus and analysis of genetic variations within the TBEV genome and will host for short-term visits researchers from Beneficiary partners Czech Republic, Slovakia and Russia.

**TBFVnet is trans-national, involving regions of active expansion of TBFVs infections** in Europe and large areas in Russia, historically endemic for TBFV, representing a reservoir of viral variants of increased pathogenicity, a potential new threat to Europe. Advanced contacts have been already established with Slovenia (xxxxxxxxxxxxxxx, University of Lubiana), Estonia (xxxxxxxxxxxxxxxx, University of Tartu) and Poland (xxxxxxxxxxxxxxxxxxxx University in Krakow), in view of expanding TBFVnet.

*What is the target group of your project? Please describe briefly what are your direct target groups and end beneficiaries?*

The consortium represents a **wide spectrum of public institutions involved in the management of TBFV infections**: veterinary (Czech Republic), healthcare (Norway) and research (Slovakia, Russia, Sweden, ICGEB).

**Direct beneficiaries are researchers and staff of partner institutes** that will benefit from knowledge exchange, collaborative research and training of young scientists. **Other target** **groups** in countries of the PPs and in other countries of the Region, which will benefit from research advancement, are:

**Health care and veterinary institutions** wishing to develop and implement in house cost-effective solutions for TBFV **Disease management research centers** involved in TBFVnet topics and available to share research tools and results Institutes wishing to develop and improve tools for TBFV surveillance

**Biotech companies** working in the field of diagnostics for infectious diseases

Governments of neighboring countries approached through the ICGEB Liaison Officers and affiliated research centers

The **population at large**, particularly groups at risk of infection: outdoor workers; people engaging leisure outdoor activities and the elderly that are the major risk group for TBE

**Target groups Description of the target groups Target value**

*Page 13/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |
| --- | --- | --- |
| Researchers/Scientists | Senior and junior scientists of PPs involved in joint research  activities, reciprocal visits to other PPs labs, joint publications and future collaborations. | 20,00 |
| Students (any age) | Other young researchers from PPs and other institutions  participating in annual seminars and actions for the dissemination of project results. | 100,00 |
| Women | Particular attention will be given to gender equality by  encouraging female scientists and other staff from PPs to actively engage in project activities such as seminars and training sessions. | 10,00 |
| General public | The lay public, including local and regional healthcare,  veterinary and research institutions, biotech companies and groups of population at major risk of infection, will benefit from project results, in particular from improved knowledge on TBFV and surveillance tools developed. | 500,00 |

***3.3 Sustainability and transferability of project outputs and results***

*How will the project ensure that outputs and outcomes have a lasting effect beyond project duration?*

*Describe concrete measures (including institutional structures, financial resources, etc.) taken during and after the project implementation to ensure and/or strengthen the sustainability* *of the project’s outputs and outcomes. Briefly explain how outputs will be further used once the project is finalised and, if relevant, explain who will be responsible and/or who will be*   
*the owner of the outputs*

*Briefly explain how outputs will be further used once the project is finalised and, if relevant, explain who will be responsible and/or who will be the owner of the outputs.*

The surveillance and diagnosis tools are produced and validated within the network. The partner institutions and the laboratories associated through **TBFVnet** benefit from the availability of **cost-effective in-house solutions** that will last beyond the end of the project reducing public costs for surveillance.

On the other hand, development of antivirals requires a high level of investment. Therefore, particular attention will be given to the identification and **protection of inventions** through filing of patents and a framework of IP policies and shared rights on inventions will be established to protect the inventors and the investment.

**Proper dissemination** tools (project website, social media, etc.) and events (regional seminars, project events) will be organized during and after project implementation to reach out to potential end beneficiaries and encourage uptake of project results. One major expected output is to have **several joint publications** on relevant scientific journals such as the Journal of Virology or Plos Journals. **Open access** will be privileged in order to make research results available to the scientific community readily and beyond project duration.

*Page 14/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

All PPs will promote **TBFVnet** in the Region through their networks. In particular, the ICGEB will promote **TBFVnet** in the Region beyond the end of the project through its communication channels and **international institutional network**. As well, **ICGEB funding programmes open to Member States** (fellowships, CRP grants, meetings and courses) will be promoted to provide additional funds for collaborative research and education on this topic.

It is expected that PPs will continue collaboration after the project and increase participation of Beneficiary countries in European funding programmes (such as H2020/Horizon Europe and others) through **joint grant applications**.

*How will the project ensure that project results are applicable and replicable by other organisations/regions/countries outside of the current partnership?*

*Describe to what extent it will be possible to transfer the project results to other organisations/regions/countries outside of the current partnership.*

The core activity of **TBFVnet** is to establish shared protocols and tools for comparable results in a wider geographic area. Therefore, the major expected output is that **Partners within** **TBEVnet will produce highly comparable and reliable results**. **These results will be made available to similar institutions working on these topics through scientific** **publications and dissemination events**. Already established contacts between Partners and fellow colleagues in Institutions in the Region will be reinforced to build an effective network. To this end, a survey will be implemented to map the relevant research groups and health/veterinary institutions in neighboring countries.

A number of activities will be set up in order to expand the TBFVnet, such as project promotion, dissemination activities, presentation of best practices, activation of own networks by each partner and mapping of relevant institutions.

In this framework, the ICGEB will be instrumental because **the ICGEB constituency includes many countries in the Region that are targeted by the Fund**: Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, North Macedonia, Turkey and Ukraine. Through activation of its programmes, in particular through its Meeting and Courses Programme, targeted events could be supported in loco both to increase sharing of data and expertise, and to transfer the outputs of TBFVnet to relevant stakeholders and the lay public. The ICGEB could also activate specific Collaborative Research Grants open to research groups in the Fund Region that are working on TBFVnet topics, in the form of CRPs ICGEB/EEA & Norway GFRC initiatives co-sponsored through TBFVnet.

***3.4 Risk assessment***

*What risks are relevant for the project? What actions will be taken to minimise their impact?*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Risk type** | **Likelihood** | **Impact** | **Relevance** | **Mitigation** |
| Poor performance of project  partners | very unlikely serious 3 All PPs have specific expertise in  the area of TBFV. This risk is very  unlikely and the supervision of the  LP will ensure activities are  performed as planned by each PP |  |  |  |

*Page 15/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  | or corrective measures are taken. A Project Steering Committee (PSC) will also be instrumental in project monitoring and guide proper dialogue among partners should there be any technical issue to examine and solve together. |
| Poor communication/cooperation  within the consortium | very unlikely | moderate | 2 | All PPs have sound experience in  European and international projects and partnerships. This risk is very unlikely and the supervision of the LP will ensure proper  communication and coordination of the consortium. PPs have already shown their willingness to build up and consolidate a research network on TBFVs, also by providing their input during the preparation of the present proposal. Some of them have previous contacts/scientific collaborations and periodically meet in scientific events. Communication activities involving PPs, such as project meetings and joint research will be further strengthened should the risk become higher. |
| Staff turnover | unlikely | minimal | 2 | All PP are solid organizations with experienced permanent staff. The execution of projects is a concerted  action of several actors, including administrative and scientific staff. In the case of personnel turnover replacements will be in place to  carry on the work and the transition phase will be supported by the  other staff. |
| Financial liquidity problems | very unlikely | serious | 3 | All PP are solid organizations with |

*Page 16/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  | governmental stakeholders, therefore the risk of financial  liquidity problems is very unlikely. In the case activities within the  program could not be accomplished a plan will be defined in accordance with the other PPs to finalize the project by providing support. All  PPs are used to work in international collaborative projects and have enough institutional resources to advance costs for implementing activities under their responsibility in each WP. |

*Page 17/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

**SECTION 4 - Planned work packages**

***WP 1***

|  |  |
| --- | --- |
| **Work package title** | Management |
| **Responsible partner** | Veterinary Research Institute |
| **Budget** | € 186.852,35 |

*How will the management on the strategic and operational level be carried out in the project? What will be the structure, responsibilities and procedures for the day-to-day management* *and co-ordination? What will the internal communication within the partnership look like? What will be the reporting and evaluation procedures? How will the risk and quality* *management be ensured? Indicate whether it is foreseen to outsource certain project management tasks.*

The Lead Partner will be responsible for the financial and technical management of the project and for liaising with the Fund Operator. A Project Manager (PM) and a Financial Manager (FM) will be in charge of the daily management of the project and will ensure proper partnership coordination, and compliance with contractual obligations in terms of implementation, visibility, reporting and funds distribution among partners. All Project Partners will contribute to a smooth and efficient implementation and reporting by timely providing the necessary information and documentations to the LP.

Project management will be carried out at two levels: at PPs level - each partner will ensure appropriate effort by technical, admin and communication staff; and, at the partnership

level, through regular communication among PPs and the setting up of a Project Steering Committee (PSC). The PSC will be composed by at least one representative for each PP, and will periodically consults to ensure appropriate guidance and monitoring of activities progression against the work plan and timetable. A project kick-off meeting will be held within M3 at the Lead Partner premises. Other project meetings will be organized on a six-month basis and hosted in turn by each PP or by conference call.

To ensure quality management and risks prevention/remediation, the PM will circulate in advance internal reports as a basis for discussion. In addition, the PM will facilitate regular exchange of information with all PPs and will monitor the realization of planned activities through regular contacts with the Responsible Partner for each WP. An internal mid-project evaluation report against the project results framework will be also prepared at the end of Y 2/beginning of Y3.

|  |  |
| --- | --- |
| **Start date** | 01/07/2020 |
| **End date** | 31/01/2024 |

**Activities**

*Please indicate activities within this WP. Attribute the start and end dates and responsible project partner to each activity. Please remember the partner shall be responsible for both* *implementation of the activity and its costs. Add as many rows as you need.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Activities** | **Forecasted start date** | **Forecasted end date** | **Name of responsible partner** |
| Daily management and liaison with the FO | 01/07/2020 | 31/01/2024 | Veterinary Research Institute |
| PSC set-up, organisation of PSC meetings  and consortium technical updates | 01/07/2020 31/01/2024 Veterinary Research Institute |  |  |
|  |  |  |  |

*Page 18/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |
| --- | --- | --- | --- |
| Co-organisation of international meetings on TBE | 01/07/2020 | 31/01/2024 | Biomedical Research Center of the Slovak  Academy of Sciences |
| Participation in PSC meetings, consortium technical updates and other project meetings | 01/07/2020 | 31/01/2024 | Biomedical Research Center of the Slovak  Academy of Sciences |
| Participation in PSC meetings, consortium technical updates and other project meetings | 01/07/2020 | 31/01/2024 | Norwegian Institute of Public Health |
| Co-organisation of international meetings on TBE | 01/07/2020 | 31/01/2024 | Veterinary Research Institute |
| Participation in PSC meetings, consortium  technical updates and other project meetings | 01/07/2020 | 31/01/2024 | International Centre for Genetic Engineering  and Biotechnology - ICGEB |
| Narrative and Financial reporting and Audits | 01/07/2020 | 31/01/2024 | Veterinary Research Institute |
| Narrative and Financial reporting and Audits | 01/07/2020 | 31/01/2024 | Biomedical Research Center of the Slovak  Academy of Sciences |
| Narrative and Financial reporting and Audits | 01/07/2020 | 31/01/2024 | Norwegian Institute of Public Health |
| Narrative and Financial reporting and Audits | 01/07/2020 | 31/01/2024 | International Centre for Genetic Engineering  and Biotechnology - ICGEB |
| Mid-term internal evaluation | 01/05/2022 | 31/12/2022 | Veterinary Research Institute |

***WP 2***

|  |  |
| --- | --- |
| **Work package title** | Communication |
| **Responsible partner** | International Centre for Genetic Engineering and Biotechnology - ICGEB |
| **Budget** | € 161.394,24 |

*What can communications do to help reach the outcomes of the project? What are the goals of the communication activities? (i.e. arise awareness, increase knowledge, influence* *attitude, change behaviour…). What kind of strategy and related approaches and/or innovative tactics will be used to reach these goals? What are the target groups of the* *communication tasks?*

*Please refer to the minimum requirements on effective communication and dissemination of results in the projects described in the Call for Proposals – Full Proposal Phase document* *under chapter “Communication and Visibility Measures“.*

Communication will be key for reaching out the project outcomes. While **emphasizing the added value of tackling TBFVs at the transnational level**, WP specific goals are to: (i) **facilitate information flows among PPs and WPs**; (ii) **disseminate project objectives and results**, in particular knowledge advancement achieved within WP3 and WP4 to promote best practices in TBFVs surveillance and antiviral drug discovery; (iii) **consolidate and expand the regional network on TBFVs**.

*Page 19/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

To ensure effective information and **compliance with FO visibility guidelines**, different communication measures and languages will be identified for each target group, i.e. leaflets, informative events, press coverage, scientific publications, conferences, etc. A dedicated website will contain the TVBFnet objectives, PPs profiles, updates on project progression through articles, photographs and other contents, and a protected area for PPs. A detailed Communication Plan will be prepared by month 3 and will include a Data Management plan and friendly guidelines for PPs staff, also focusing on the acknowledgement of the Donor and on public awareness on the project.

**Communication target groups vs communication actions**:

Researchers and other staff of PPs - internal communication, project meetings, project website (and intranet), biannual bulletins

Scientific community - scientific publications, international conferences, regional seminars (as organised within WP3)

Health, veterinary and research institutions and biotech companies, at national and regional level - project website, regional seminars, project events Lay public - project website, project events

**All PPs will devote specific resources to contribute to communication activities and will provide necessary contents related to their project activities**. The ICGEB, that has extensive experience in outreach activities at the international level, will coordinate the WP in close contact with the LP. In particular, an Outreach Officer and the ICGEB postdoctoral researcher working on TBFVnet, supported by other internal and external resources as necessary, will ensure communication tasks are properly handled. As well, the LP will ensure

the contribution of a Project and Communication Manager of VRI.

**ICGEB will also exploit its own network of Member Countries to approach key laboratories in TBFVs research and surveillance in the area** (Bosnia and Herzegovina, Bulgaria, Croatia, Hungary, Moldova, Montenegro, North Macedonia, Romania, Slovenia, Serbia, Turkey). Other non-ICGEB neighboring countries of interest for EEA Norway will be approached through scientific contacts (Albania, Belarus, Estonia, Greece, Latvia, Lithuania, Poland, Ukraine). Interested labs will be involved to share data, protocols and reagents, upon specific agreements with the TBFVnet. NIPH will contribute with its networks in Scandinavia and Europe.

|  |  |
| --- | --- |
| **Start date** | 01/07/2020 |
| **End date** | 31/01/2024 |

**Activities**

*Please indicate activities within this WP. Attribute the start and end dates and project partner to each activity. Please remember the partner shall be responsible for both implementation* *of the activity and its costs. Add as many rows as you need.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Activities** | **Forecasted start date** | **Forecasted end date** | **Name of responsible partner** |
| Development of communication plan -  Reopen | 01/07/2020 31/12/2022 International Centre for Genetic Engineering  and Biotechnology - ICGEB |  |  |
| Identification of key stakeholders in PPs countries and in other countries in the target Region | 01/08/2020 | 31/12/2023 | International Centre for Genetic Engineering  and Biotechnology - ICGEB |
| Organisation of the launching event | 01/07/2020 | 31/07/2020 | Veterinary Research Institute |
|  |  |  |  |

*Page 20/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |
| --- | --- | --- | --- |
| Creation of project website and production of leaflets and other promotional materials | 01/07/2020 | 31/12/2020 | International Centre for Genetic Engineering  and Biotechnology - ICGEB |
| Preparation of web updates, posts on social media and six-month bulletins | 01/11/2020 | 31/01/2024 | International Centre for Genetic Engineering  and Biotechnology - ICGEB |
| Scientific publications (OA) and  presentations in scientific conferences such as the International Congress of Virology, Czechoslovak Conference of Virology, Ticks and Tick-borne Diseases meeting | 01/03/2022 | 31/01/2024 | Veterinary Research Institute |
| Enhancement and Strenghtening of Social Media Coverage and Visibility of the Project | 01/05/2022 | 31/01/2024 | International Centre for Genetic Engineering  and Biotechnology - ICGEB |
| Scientific publications (OA) and presentations of results in national and international scientific conferences such as ISTTBD in Weimar, Czechoslovak Virology Conference in Brno, and others | 01/03/2022 | 31/01/2024 | Biomedical Research Center of the Slovak  Academy of Sciences |
| Scientific publications (OA) and presentations of results in national and international scientific conferences such as TTP10, JENA conference, Nor-Tick and SNÄFF | 01/03/2022 | 31/01/2024 | Norwegian Institute of Public Health |
| Scientific publications (OA) and presentations in international conferences (European Congress of Virology, Positive- Strand RNA Viruses Keystone Symposium, Gordon conference on cells and viruses) | 01/03/2022 | 31/01/2024 | Biomedical Research Center of the Slovak  Academy of Sciences |
| Scientific publications (OA) and presentations in national and international conferences such as European Congress of Virology, American Society of Virology, Gordon and Keystone meetings of Virology | 01/03/2022 | 31/01/2024 | International Centre for Genetic Engineering  and Biotechnology - ICGEB |
| TBFVnet closing event | 01/10/2023 | 31/01/2024 | Veterinary Research Institute |

***WP 3***

|  |  |
| --- | --- |
| **Work package title** | Training and transfer of knowledge on surveillance at the regional level |

*Page 21/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |
| --- | --- |
| **Responsible partner** | Norwegian Institute of Public Health |
| **Budget** | € 419.487,20 |

*Please describe the work package.*

*What is the purpose of the work package? What are the target groups of the work package (if applicable)?What activities will be undertaken within the work package? How will activities* *undertaken in this work package contribute to the outputs and outcomes of the project?*

The aim of WP3 is to **establish shared tools and protocols for the comparable diagnosis and surveillance of TBFV in animals and humans**. Procedures to be implemented for TBFVs identification include molecular and serological techniques that are able to detect directly the pathogen or indirectly the immune response of the host. WP3 therefore foresees the **implementation and dissemination of specific diagnostic assays to all countries involved** through two complimentary activities coordinated by NIPH.

Three **regional seminars** on diagnostics and surveillance will be organised to disseminate the tools validated at NIPH also to neiboughring countries at the regional level.

**Development of serological tests.** Partner ICGEB has developed a novel ELISA based on the recombinant TBFV NS1 antigen. This assay has been validated on clinical samples   
and showed a high sensitivity and specificity, allowing also the detection of vaccine brake-through cases that are a concern particularly for the elderly. ICGEB will make this test available to NIPH first, and then to all TBFVnet partners for the analysis of TBEV IgM/G. **Practical training of one-week duration will be given at ICGEB to all PPs**. This NS1 ELISA will be expanded to POWV, OHFV and LIV and tested in experimentally infected animals at CFSC to evaluate sensitivity and cross-reactivity. In addition, CFSC and ICGEB will exchange research material and one researcher from ICGEB will visit CFSC for a period of 1 month.

**Development of molecular tests.** Sensitive and specific Real-Time PCR and Next Generation Sequencing techniques (NGS) for high viral load TBEV have been developed at NIPH. **A standardized protocol of RT-PCR will be implemented for TBEV and shared among partners** thorough a written protocol with associated standards and controls developed at NIPH. A **databank of TBFV sequences** to be linked to the European Virus Archive (EVAg) will be prepared by VRI with the inputs from CFSC, SAS and NIPH. New sets of primers   
and probes for RT PCR of TBFV will be tested at NIPH. A pipeline for direct sequencing of viral samples will be implemented at NIPH and used to detect TBFV isolates from the field collected in 2 joint seasonal expeditions from NIPH and CFSC. These sequences will be further added to the databank.

Serological and molecular tests will be validated using human samples adhering stricktly to the ethical regulation of the partners' countries and health institutions.

|  |  |
| --- | --- |
| **Start date** | 01/07/2020 |
| **End date** | 31/01/2024 |

**Outcomes and Outputs**

*Please select the outcomes and outputs to which this work package will contribute.*

|  |  |
| --- | --- |
| **Outcome** | **Outputs** |

*Page 22/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |
| --- | --- |
| Enhanced performance of research institutions | Training on diagnostic assays delivered |
| Enhanced cooperation and improved mutual knowledge and understanding between the donor and beneficiary states. | Scientific interaction between Donor and Beneficiary States facilitated |

**Outputs and Activities**

*For each output, which will be produced in this work package, describe the activities needed to achieve it. Please indicate start and end dates and project partner to each activity.* *Please remember the Partner shall be responsible for both implementation of the activity and its costs.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outputs** | **Activities** | **Forecasted start date** | **Forecasted end date** | **Name of responsible partner** |
| Training on diagnostic assays  delivered | Preparation and exchange of  research material and training on  TBEV NS1 based ELISA | 01/08/2020 31/12/2022 International Centre for Genetic  Engineering and Biotechnology -  ICGEB |  |  |
| One-week training at the ICGEB for Beneficiary partner VRI | 01/06/2021 | 31/01/2024 | Veterinary Research Institute |
| One-week training at the ICGEB for Expertise partner NIPH | 01/07/2022 | 31/12/2023 | Norwegian Institute of Public Health |
| One-week training at the ICGEB for Beneficiary partner SAS | 01/06/2021 | 31/10/2021 | Biomedical Research Center of the  Slovak Academy of Sciences |
| One-week training at the ICGEB for Donor State NIPH | 01/06/2021 | 31/01/2024 | Norwegian Institute of Public Health |
| Experiments at NIPH (POWV, OHFV and LIV NS1 based ELISA) | 01/05/2021 | 31/05/2023 | Norwegian Institute of Public Health |
| One-month visit at ICGEB for tests validation (POWV, OHFV and LIV NS1 based ELISA) | 01/01/2023 | 31/12/2023 | Norwegian Institute of Public Health |
| Collection of ticks and measurements of climatic parameters | 01/07/2020 | 31/01/2024 | Norwegian Institute of Public Health |
| Test and evaluation of TBEV NS1 based ELISA | 01/07/2020 | 30/11/2023 | Norwegian Institute of Public Health |
| Creation of a databank of TBFV sequences and availability of the same to the scientific community | 01/10/2020 | 30/09/2023 | Veterinary Research Institute |
| Set up of diagnostics for TBEV | 01/08/2020 | 30/11/2023 | Biomedical Research Center of the  Slovak Academy of Sciences |

*Page 23/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Test of new set of RT PCR primers for TBFV diagnosis | 01/10/2021 | 31/05/2023 | Norwegian Institute of Public Health |
| Scientific interaction between Donor and Beneficiary States facilitated | Preparation and sharing of diagnostic protocol for TBEV RT PCR with standards and controls with all PPs and expanded network, and delivery of short term training sessions to Beneficiary Partners | 01/07/2020 | 31/01/2024 | Norwegian Institute of Public Health |
| Development of pipeline for direct sequencing of viral isolates and tested on the field | 01/08/2020 | 31/08/2023 | Norwegian Institute of Public Health |
| Short term training of staff at NIPH for RT PCR and sequencing for Beneficiary partner VRI | 01/10/2020 | 30/11/2023 | Veterinary Research Institute |
| Short term training of staff at NIPH for RT PCR and sequencing for Beneficiary partner ICGEB | 01/11/2022 | 31/12/2023 | International Centre for Genetic  Engineering and Biotechnology - ICGEB |
| Short term training of staff at NIPH for RT PCR and sequencing for Beneficiary partner SAS | 01/10/2020 | 30/11/2023 | Biomedical Research Center of the  Slovak Academy of Sciences |
| TBFVnet (first) regional seminar | 01/08/2021 | 31/01/2024 | Norwegian Institute of Public Health |
| TBFVnet (second) regional seminar | 01/08/2022 | 31/10/2022 | International Centre for Genetic  Engineering and Biotechnology - ICGEB |
| TBFVnet (third) regional seminar | 01/08/2023 | 31/10/2023 | Biomedical Research Center of the  Slovak Academy of Sciences |

***WP 4***

|  |  |
| --- | --- |
| **Work package title** | Collaborative research for antiviral drug discovery |
| **Responsible partner** | Biomedical Research Center of the Slovak Academy of Sciences |
| **Budget** | € 571.174,66 |

*Please describe the work package.*

*What is the purpose of the work package? What are the target groups of the work package (if applicable)?What activities will be undertaken within the work package? How will activities*

*Page 24/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

*undertaken in this work package contribute to the outputs and outcomes of the project?*

The aim of WP4 is to **provide a shared research framework to study TBFV pathogenesis in order to quickly respond to TBFV infections** with the appropriate treatments. Molecular correlates of TBFV pathogenesis will be studied taking advantage of the expertise partners MIMS and ICGEB. Models of tick-borne transmission, infection and tissue tropism will be available at VRI, CFSC and SAS. WP4 therefore aims at the implementation of models of TBFV pathogenesis designed to test antiviral strategies. All in vivo studies will be conducted according to national and international ethical standards.

**Research on the pathogenesis of TBFVs.** Models of TBEV pathogenesis *in vivo* have been developed by VRI, CFSC and SAS. These include tick-bite route of infection. Comparative studies of tissue invasion and viral spread using different strains of TBFV will be conducted applying the same protocols in different laboratories and sharing reagents. PPs will share information (through meetings and conference calls) about their respective models and define comparative studies to be then implemented by the junior scientists in their respective institutions. A **junior scientist from VRI, SAS and CFSC will make shorter and longer visits in each other laboratory to confront protocols and reagents**. Readout assays will include novel molecular tools and imaging technologies implemented by expertise partners MIMS and ICGEB. A junior scientist from CFSC will visit ICGEB for 2 months, while a junior scientist from VRI will visit MIMS three times for 2 months each.

**Research on drug discovery.** Partners VRI and CFSC, as well as expertise partners ICGEB and MIMS, have a pipeline for drug discovery and neutralizing antibodies that will be tested in **cross-laboratory experiments**. This will be implemented by defining a common strategy of antiviral testing from *in vitro* to *in vivo* by constant interactions through conference calls and exchange of protocols and reagents between laboratories. A junior scientist from CFSC, ICGEB and MIMS will visit SAS (4 months) to test antiviral strategies in a model of tick-bite infection that has been uniquely established in this laboratory. A general scheme for data sharing and IP protection will be implemented by ICGEB.

|  |  |
| --- | --- |
| **Start date** | 01/07/2020 |
| **End date** | 31/01/2024 |

**Outcomes and Outputs**

*Please select the outcomes and outputs to which this work package will contribute.*

|  |  |
| --- | --- |
| **Outcome** | **Outputs** |
| Enhanced performance of research institutions | Cross-labs experiments for antiviral drug discovery conducted |

**Outputs and Activities**

*For each output, which will be produced in this work package, describe the activities needed to achieve it. Please indicate start and end dates and project partner to each activity.* *Please remember the Partner shall be responsible for both implementation of the activity and its costs.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outputs** | **Activities** | **Forecasted start date** | **Forecasted end date** | **Name of responsible partner** |

*Page 25/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cross-labs experiments for antiviral drug discovery conducted | Exchange of junior staff (one month total time for each visit for the duration of the activity) of VRI to SAS for the definition of a common strategy on TBFV pathogenesis studies | 01/06/2021 | 30/09/2022 | Veterinary Research Institute |
| Exchange of junior staff of ICGEB  to SAS (1 month) & VRI (2 months) for the definition of a common strategy on TBFV pathogenesis studies and antiviral drug discovery | 01/09/2022 | 31/12/2023 | International Centre for Genetic  Engineering and Biotechnology - ICGEB |
| Exchange of junior staff (one month total time for each visit for the duration of the activity) of SAS to VRI for the definition of a common strategy on TBFV pathogenesis studies | 01/06/2022 | 30/09/2022 | Biomedical Research Center of the  Slovak Academy of Sciences |
| 2-month visit to ICGEB for the definition of novel readout techniques with expertise partners | 01/09/2022 | 01/11/2022 | Biomedical Research Center of the  Slovak Academy of Sciences |
| 6-month visit to MIMS for the definition of novel readout techniques with expertise partners | 01/05/2021 | 30/11/2022 | Veterinary Research Institute |
| Development and implementation of novel imaging techniques | 01/05/2021 | 31/12/2023 | Veterinary Research Institute |
| Set up of in vivo models for testing | 01/09/2021 | 31/08/2023 | Veterinary Research Institute |
| Preparation for cross-labs  experiments for testing of antiviral  strategies on a model of tick bite  infection | 01/05/2022 31/12/2023 Biomedical Research Center of the  Slovak Academy of Sciences |  |  |
| Exchange of junior staff of MIMS to VRI (one month total time for each visit for the duration of the activity) | 01/05/2022 | 31/12/2023 | Veterinary Research Institute |
| Preliminary studies on TBFV pathogenesis and antiviral drug discovery | 01/05/2022 | 31/01/2024 | International Centre for Genetic  Engineering and Biotechnology - ICGEB |

*Page 26/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Definition of a general scheme for IP protection in the context of reagents exchange | 30/11/2020 | 31/08/2021 | International Centre for Genetic  Engineering and Biotechnology - ICGEB |
| External collaboration with Network members | 01/05/2022 | 31/12/2023 | International Centre for Genetic  Engineering and Biotechnology - ICGEB |

*Page 27/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

**SECTION 5 - Project budget**

***5.1 Detailed Project Budget***

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Activity** | **Cost description** | **Budget heading** | **Unit type** | **Nb. of units** | **Unit cost (EUR)** | **Amount (EUR)** | **Total estimated** **eligible direct costs**  **per activity (EUR)** |
| Daily management and liaison with the FO | Project manager  (admin, financial and  communication), 30%  time equivalent | BH1 - Staff Costs Month 43,00 454,97 19.563,71 19.563,71 |  |  |  |  |  |
| PSC set-up, organisation of PSC meetings and consortium technical updates | Principal Investigator (xxxxxxxxxxxx) | BH1 - Staff Costs | Month | 4,80 | 3.769,00 | 18.091,20 | 25.091,20 |
| Travel costs in  relation to Czech regulations (per diem, accommodation, airfare) | BH2 - Travel Costs and Related Subsistence Allowances | Item | 14,00 | 500,00 | 7.000,00 |
| Co-organisation of international meetings on TBE | Transport - person/round trip | BH2 - Travel Costs and Related Subsistence Allowances | Item | 14,00 | 600,00 | 8.400,00 | 21.280,00 |
| Per diem (incl. accommodation)/4 day trip | BH2 - Travel Costs and Related Subsistence Allowances | Item | 14,00 | 920,00 | 12.880,00 |
| Participation in PSC meetings, consortium technical updates and other project  meetings | Principal Investigator | BH1 - Staff Costs | Month | 1,00 | 2.832,00 | 2.832,00 | 19.032,00 |
| Per diem (incl.  accommodation) | BH2 - Travel Costs  and Related  Subsistence  Allowances | Day 52,00 150,00 7.800,00 |  |  |  |
| Transport - roundtrip/person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 14,00 | 600,00 | 8.400,00 |

*Page 28/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Participation in PSC meetings, consortium technical updates and other project  meetings | Travel cost in relation to Norwegian regulations for one person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 8,00 | 1.200,00 | 9.600,00 | 33.600,00 |
| Travel expenses for internal and external investigators and junior researchers, conference meals including dinner | BH2 - Travel Costs and Related Subsistence Allowances | Item | 5,00 | 4.800,00 | 24.000,00 |
| Co-organisation of international meetings on TBE | Travel, hotel to attend the meetings. The meeting includes the PSC, necessary technical meetings,  the TBFVnet regional seminar 1-3 and the closing event. One item is all costs associated with the meeting for one  person and the unit is number of people attending from MIMS. | BH2 - Travel Costs and Related Subsistence Allowances | Item | 10,00 | 800,00 | 8.000,00 | 8.000,00 |
| Participation in PSC meetings, consortium technical updates and other project  meetings | Principal Investigator, 0,25months FTE | BH1 - Staff Costs | Month | 0,40 | 11.000,00 | 4.400,00 | 9.400,00 |
| Travel costs for PI and/or other ICGEB staff involved in the project, including transport and DSA/accommodation | BH2 - Travel Costs and Related Subsistence Allowances | Item | 5,00 | 1.000,00 | 5.000,00 |
| Narrative and Financial reporting and Audits | Costs for audit | BH5 - Project  Contract Requirements Costs | Item | 8,00 | 500,00 | 4.000,00 | 4.000,00 |
| Narrative and | Principal Investigator | BH1 - Staff Costs | Month | 1,00 | 2.832,00 | 2.832,00 | 5.832,00 |

*Page 29/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Financial reporting and Audits | Audit costs for the entire project | BH5 - Project Contract Requirements Costs | Item | 8,00 | 375,00 | 3.000,00 |  |
| Narrative and Financial reporting and Audits | Audit costs, administration and ordering expenses, budget revision | BH5 - Project Contract Requirements Costs | Service | 8,00 | 450,00 | 3.600,00 | 3.600,00 |
| Narrative and Financial reporting and Audits | Financial Manager, 2m FTE | BH1 - Staff Costs | Month | 3,70 | 5.900,00 | 21.830,00 | 26.430,00 |
| Costs for project audits | BH5 - Project Contract Requirements Costs | Item | 8,00 | 575,00 | 4.600,00 |
| Mid-term internal evaluation | Project manager (admin, financial and communication), 25% time equivalent | BH1 - Staff Costs | Month | 2,00 | 257,00 | 514,00 | 514,00 |
| Development of communication plan - Reopen | Outreach & communication officer, 0,5m FTE | BH1 - Staff Costs | Month | 0,50 | 8.833,00 | 4.416,50 | 6.416,50 |
| Costs for external service/collaborator for communication activities | BH6 - Subcontracting Costs | Service | 1,00 | 2.000,00 | 2.000,00 |
| Identification of key stakeholders in PPs countries and in other countries in the target Region | Researcher 1m FTE | BH1 - Staff Costs | Month | 1,00 | 4.000,00 | 4.000,00 | 7.000,00 |
| Costs for external  service/collaborator  for communication  activities | BH6 - Subcontracting  Costs | Service 1,00 3.000,00 3.000,00 |  |  |  |
| Organisation of the launching event | Principal Investigator (xxxxxxxxxxxx) | BH1 - Staff Costs | Month | 1,00 | 3.769,00 | 3.769,00 | 6.269,00 |
| Rental of lecture room and presentation technique, catering | BH6 - Subcontracting Costs | Item | 1,00 | 2.500,00 | 2.500,00 |

*Page 30/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Creation of project website and  production of leaflets and other promotional materials | Costs for external service | BH6 - Subcontracting Costs | Service | 1,00 | 2.500,00 | 2.500,00 | 2.500,00 |
| Preparation of web updates, posts on social media and six- month bulletins | Outreach & communication officer, 1,5m FTE | BH1 - Staff Costs | Month | 1,50 | 8.833,00 | 13.249,50 | 17.249,50 |
| Researcher 1m FTE | BH1 - Staff Costs | Month | 1,00 | 4.000,00 | 4.000,00 |
| Scientific publications (OA) and presentations in scientific conferences such as the International  Congress of Virology, Czechoslovak Conference of Virology, Ticks and Tick-borne Diseases meeting | Principal Investigator (xxxxxxxxxxx) | BH1 - Staff Costs | Month | 2,80 | 3.769,00 | 10.553,20 | 18.053,20 |
| Open access publishing costs | BH6 - Subcontracting Costs | Item | 3,00 | 1.500,00 | 4.500,00 |
| Travel costs in  relation to Czech regulations (per diem, accommodation, airfare) | BH2 - Travel Costs and Related Subsistence Allowances | Item | 6,00 | 500,00 | 3.000,00 |
| Enhancement and Strenghtening of  Social Media  Coverage and  Visibility of the Project | Outreach & communication officer, 2.5m FTE | BH1 - Staff Costs | Month | 2,50 | 8.833,00 | 22.082,50 | 27.582,50 |
| Costs for external service/collaborator for communication activities | BH6 - Subcontracting Costs | Item | 1,00 | 5.500,00 | 5.500,00 |
| Scientific publications (OA) and  presentations of  results in national and international scientific conferences such as ISTTBD in Weimar, Czechoslovak | Principal investigator | BH1 - Staff Costs | Month | 2,00 | 2.832,00 | 5.664,00 | 13.664,00 |

*Page 31/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Virology Conference in Brno, and others | Per diem (incl. accommodation) day for participation in scientific conferences | BH2 - Travel Costs and Related Subsistence Allowances | Day | 8,00 | 150,00 | 1.200,00 |  |
| Open access publication fees | BH6 - Subcontracting Costs | Item | 2,00 | 2.000,00 | 4.000,00 |
| Transport for participation in scientific conferences  - roundtrip per person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 2,00 | 600,00 | 1.200,00 |
| Registration fees - person/conference | BH6 - Subcontracting Costs | Item | 2,00 | 800,00 | 1.600,00 |
| Scientific publications (OA) and  presentations of  results in national and international scientific conferences such as TTP10, JENA conference, Nor-Tick and SNÄFF | Publication costs | BH6 - Subcontracting  Costs | Item | 2,00 | 2.400,00 | 4.800,00 | 10.800,00 |
| Travel costs and allowances for participation in conferences in  relation to Norwegian regulations for one person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 5,00 | 1.200,00 | 6.000,00 |
| Scientific publications (OA) and presentations in international conferences (European Congress of Virology, Positive- Strand RNA Viruses Keystone  Symposium, Gordon conference on cells and viruses) | Costs associated with publication in peer review international journals, one item one publication | BH6 - Subcontracting Costs | Item | 4,00 | 2.500,00 | 10.000,00 | 22.000,00 |
| Registration, travel  and hotel costs to attend international conferences and present data from the projects - one item for one person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 6,00 | 2.000,00 | 12.000,00 |
| Scientific publications (OA) and presentations in | Principal Investigator, 0,1months FTE | BH1 - Staff Costs | Month | 0,10 | 11.000,00 | 1.100,00 | 12.100,00 |

*Page 32/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| national and international conferences such as  European Congress  of Virology, American Society of Virology, Gordon and Keystone meetings of Virology | Researcher 1m FTE | BH1 - Staff Costs | Month | 1,00 | 4.000,00 | 4.000,00 |  |
| Travel costs for PI and/or researcher, including transport and  DSA/accommodation, | BH2 - Travel Costs  and Related  Subsistence  Allowances | Item 2,00 1.000,00 2.000,00 |  |  |  |
| Costs for scientific publications | BH6 - Subcontracting Costs | Item | 2,00 | 2.500,00 | 5.000,00 |
| TBFVnet closing event | Principal Investigator (Prof. Ruzek) | BH1 - Staff Costs | Month | 1,00 | 3.769,00 | 3.769,00 | 6.269,00 |
| Rental of lecture room and presentation technique, catering | BH6 - Subcontracting Costs | Item | 1,00 | 2.500,00 | 2.500,00 |
| Preparation and exchange of research material and training on TBEV NS1 based ELISA | Principal Investigator, 0,25months FTE | BH1 - Staff Costs | Month | 0,25 | 11.000,00 | 2.750,00 | 138.750,00 |
| Researcher 22m FTE | BH1 - Staff Costs | Month | 22,00 | 4.000,00 | 88.000,00 |
| Reagents and lab  consumables  estimated costs for  project activities  12,000 E/Y | BH3 - Consumables  and Supplies | Set 4,00 12.000,00 48.000,00 |  |  |  |
| One-week training at the ICGEB for Beneficiary partner VRI | Researcher | BH1 - Staff Costs | Month | 2,00 | 2.301,00 | 4.602,00 | 8.102,00 |
| Travel costs in  relation to Czech  regulations (per diem,  accommodation,  airfare) | BH2 - Travel Costs  and Related  Subsistence  Allowances | Item 7,00 500,00 3.500,00 |  |  |  |
| One-week training at the ICGEB for Expertise partner NIPH | Per diem (incl. accommodation) / person/5 day trip | BH2 - Travel Costs and Related Subsistence Allowances | Item | 1,00 | 1.150,00 | 1.150,00 | 1.750,00 |
| Transport | BH2 - Travel Costs  and Related Subsistence Allowances | Item | 1,00 | 600,00 | 600,00 |

*Page 33/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| One-week training at the ICGEB for Beneficiary partner SAS | Per diem (incl. accommodation) | BH2 - Travel Costs and Related Subsistence Allowances | Day | 5,00 | 150,00 | 750,00 | 1.350,00 |
| Transport - roundtrip/person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 1,00 | 600,00 | 600,00 |
| One-week training at the ICGEB for Donor State NIPH | Travel cost in relation to Norwegian regulations for one person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 1,00 | 1.500,00 | 1.500,00 | 1.500,00 |
| Experiments at NIPH (POWV, OHFV and LIV NS1 based ELISA) | Supplies (plastics and reagents) | BH3 - Consumables and Supplies | Item | 1,00 | 6.000,00 | 6.000,00 | 10.500,00 |
| Laboratory animals / 30 mice | BH3 - Consumables and Supplies | Set | 3,00 | 250,00 | 750,00 |
| Laboratory animals (housing costs) / 30 mice/per day | BH3 - Consumables and Supplies | Set | 75,00 | 50,00 | 3.750,00 |
| One-month visit at ICGEB for tests validation (POWV, OHFV and LIV NS1 based ELISA) | Researcher 2m FTE | BH1 - Staff Costs | Month | 2,00 | 4.000,00 | 8.000,00 | 11.000,00 |
| Travel costs for  researcher including  accommodation and  living/DSA | BH2 - Travel Costs  and Related  Subsistence  Allowances | Item 1,00 3.000,00 3.000,00 |  |  |  |
| Collection of ticks and measurements of climatic parameters | Travel cost in relation to Norwegian regulations for one person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 3,00 | 5.000,00 | 15.000,00 | 15.000,00 |
| Test and evaluation of TBEV NS1 based ELISA | Costs for comparison of TBEV NS1 ELISA to commercial kits used for reference function | BH3 - Consumables and Supplies | Item | 6,00 | 500,00 | 3.000,00 | 3.000,00 |

*Page 34/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Creation of a databank of TBFV sequences and availability of the same to the scientific community | Researcher | BH1 - Staff Costs | Month | 12,00 | 2.301,00 | 27.612,00 | 27.612,00 |
| Set up of diagnostics for TBEV | Postdoc researchers | BH1 - Staff Costs | Month | 12,00 | 1.772,00 | 21.264,00 | 66.784,00 |
| Technician | BH1 - Staff Costs | Month | 12,00 | 1.002,00 | 12.024,00 |
| Principal Investigator | BH1 - Staff Costs | Month | 3,00 | 2.832,00 | 8.496,00 |
| Consumables for serological work and for RT-PCR and NGS | BH3 - Consumables  and Supplies | Item 1,00 25.000,00 25.000,00 |  |  |  |
| Test of new set of RT PCR primers for  TBFV diagnosis | Consumables and supplies and freight cost | BH3 - Consumables and Supplies | Item | 5,00 | 800,00 | 4.000,00 | 4.000,00 |
| Preparation and sharing of diagnostic protocol for TBEV RT PCR with standards and controls with all PPs and expanded network, and delivery of short term training sessions to Beneficiary Partners | Cultivation of reference virus and freight cost | BH3 - Consumables and Supplies | Service | 4,00 | 700,00 | 2.800,00 | 2.800,00 |
| Development of pipeline for direct sequencing of viral isolates and tested on the field | Cultivation of virus, Primers, Kapa hyper plus kits, MiSeq NGS kits, MinIon library prep with barcodes, MinIon flow cells | BH3 - Consumables and Supplies | Item | 6,00 | 4.625,00 | 27.750,00 | 27.750,00 |
| Short term training of staff at NIPH for RT PCR and sequencing for Beneficiary partner VRI | Researcher | BH1 - Staff Costs | Month | 10,00 | 2.301,00 | 23.010,00 | 24.510,00 |

*Page 35/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Travel costs in  relation to Czech regulations (per diem, accommodation, airfare) events organized by FO | BH2 - Travel Costs and Related Subsistence Allowances | Item | 3,00 | 500,00 | 1.500,00 |  |
| Short term training of staff at NIPH for RT PCR and sequencing for Beneficiary partner ICGEB | Travel & and Accounts Assistant | BH1 - Staff Costs | Month | 1,00 | 4.000,00 | 4.000,00 | 20.200,00 |
| Per diem (incl. accommodation) for max 1 month stay (at least 2 travels) | BH2 - Travel Costs and Related Subsistence Allowances | Item | 2,00 | 5.000,00 | 10.000,00 |
| Consumables to be used during training | BH3 - Consumables and Supplies | Item | 1,00 | 5.000,00 | 5.000,00 |
| Transport EUR/person/round trip x2 | BH2 - Travel Costs and Related Subsistence Allowances | Item | 2,00 | 600,00 | 1.200,00 |
| Short term training of staff at NIPH for RT PCR and sequencing for Beneficiary partner SAS | Per diem (incl. accommodation) | BH2 - Travel Costs and Related Subsistence Allowances | Day | 5,00 | 150,00 | 750,00 | 1.350,00 |
| Transport - roundtrip/person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 1,00 | 600,00 | 600,00 |
| TBFVnet (first) regional seminar | Organisation costs, travel expenses for speakers and external  partners of NIPH, conference meals including dinner | BH6 - Subcontracting Costs | Service | 1,00 | 7.403,00 | 7.403,00 | 7.403,00 |
| TBFVnet (second) regional seminar | Principal Investigator, 0,25months FTE | BH1 - Staff Costs | Month | 0,25 | 11.000,00 | 2.750,00 | 7.750,00 |

*Page 36/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Organisation of the seminar - Costs for external  service/collaborator for communication activities | BH6 - Subcontracting Costs | Service | 1,00 | 5.000,00 | 5.000,00 |  |
| TBFVnet (third) regional seminar | Costs related with the seminar organisation | BH6 - Subcontracting Costs | Service | 1,00 | 8.000,00 | 8.000,00 | 8.000,00 |
| Exchange of junior  staff (one month total time for each visit for the duration of the activity) of VRI to SAS for the definition of a common strategy on TBFV pathogenesis studies | Researcher | BH1 - Staff Costs | Month | 6,00 | 2.301,00 | 13.806,00 | 19.806,00 |
| Travel costs in  relation to Czech  regulations (per diem,  accommodation,  airfare) | BH2 - Travel Costs  and Related  Subsistence  Allowances | Item 12,00 500,00 6.000,00 |  |  |  |
| Exchange of junior staff of ICGEB to SAS (1 month) & VRI (2 months) for the definition of a  common strategy on TBFV pathogenesis studies and antiviral drug discovery | Per diem (incl. accommodation) / EUR/person/1 month trip | BH2 - Travel Costs and Related Subsistence Allowances | Item | 3,00 | 3.800,00 | 11.400,00 | 13.200,00 |
| Transport - EUR/person/round trip | BH2 - Travel Costs and Related Subsistence Allowances | Item | 3,00 | 600,00 | 1.800,00 |
| Exchange of junior  staff (one month total time for each visit for the duration of the activity) of SAS to VRI for the definition of a common strategy on TBFV pathogenesis studies | Per diem (incl. accommodation) | BH2 - Travel Costs and Related Subsistence Allowances | Day | 45,00 | 150,00 | 6.750,00 | 7.950,00 |
| Transport - roundtrip/person | BH2 - Travel Costs and Related Subsistence Allowances | Item | 2,00 | 600,00 | 1.200,00 |

*Page 37/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 2-month visit to ICGEB for the definition of novel readout techniques with expertise partners | Per diem (incl. accommodation) - EUR/person/2 month trip | BH2 - Travel Costs and Related Subsistence Allowances | Item | 1,00 | 7.000,00 | 7.000,00 | 7.600,00 |
| Transport - EUR/person/round trip | BH2 - Travel Costs and Related Subsistence Allowances | Item | 1,00 | 600,00 | 600,00 |
| 6-month visit to MIMS for the definition of novel readout techniques with expertise partners | Researcher | BH1 - Staff Costs | Month | 6,00 | 2.301,00 | 13.806,00 | 17.306,00 |
| Travel costs in  relation to Czech  regulations (per diem,  accommodation,  airfare) | BH2 - Travel Costs  and Related  Subsistence  Allowances | Item 7,00 500,00 3.500,00 |  |  |  |
| Development and implementation of novel imaging  techniques | To develop and implement the whole brain imaging a permanent staff in MIMS will work on the project over 41  months at 50% | BH1 - Staff Costs | Month | 41,00 | 2.330,00 | 95.530,00 | 137.880,00 |
| Consumable costs involved in performing the whole brain imaging as well as  user fees of the microscopes. Monthly cost is indicated as consumables and  user fees | BH3 - Consumables and Supplies | Month | 41,00 | 850,00 | 34.850,00 |
| Shipping costs for sending reagents to the different partners. Sending BLS3 classified viruses with world courier. | BH3 - Consumables and Supplies | Item | 3,00 | 2.500,00 | 7.500,00 |

*Page 38/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Set up of in vivo models for testing | Researcher | BH1 - Staff Costs | Month | 12,00 | 2.301,00 | 27.612,00 | 82.906,40 |
| Lab technician | BH1 - Staff Costs | Month | 14,40 | 1.201,00 | 17.294,40 |
| Purchase of mice,  probes, anaesthesia,  mouse bedding and  diet, chemicals, PPE | BH3 - Consumables  and Supplies | Item 1,00 38.000,00 38.000,00 |  |  |  |
| Preparation for cross- labs experiments for testing of antiviral strategies on a model of tick bite infection | Postdoctoral researchers | BH1 - Staff Costs | Month | 24,00 | 1.772,00 | 42.528,00 | 101.114,00 |
| Technician | BH1 - Staff Costs | Month | 12,00 | 1.002,00 | 12.024,00 |
| Principal Investigator | BH1 - Staff Costs | Month | 3,00 | 2.832,00 | 8.496,00 |
| Consumables for RT- PCR and NGS | BH3 - Consumables  and Supplies | Item 1,00 38.066,00 38.066,00 |  |  |  |
| Exchange of junior staff of MIMS to VRI (one month total time for each visit for the duration of the activity) | Travel and hotel for MIMS personnel going to SAS, during one month at a time | BH2 - Travel Costs and Related Subsistence Allowances | Month | 4,00 | 1.500,00 | 6.000,00 | 6.000,00 |
| Preliminary studies on TBFV pathogenesis and antiviral drug discovery | Post Doc Student 16 months | BH1 - Staff Costs | Month | 16,00 | 2.050,00 | 32.800,00 | 100.917,00 |
| Principal Investigator, 3 months FTE | BH1 - Staff Costs | Month | 3,00 | 11.000,00 | 33.000,00 |
| Researcher 5 m FTE | BH1 - Staff Costs | Month | 5,00 | 4.000,00 | 20.000,00 |
| Supplies (plastic and reagents) | BH3 - Consumables  and Supplies | Item 1,00 15.117,00 15.117,00 |  |  |  |
| Definition of a general scheme for IP protection in the context of reagents exchange | Principal Investigator, 0,15months FTE | BH1 - Staff Costs | Month | 0,15 | 11.000,00 | 1.650,00 | 5.792,00 |
| Knowledge Transfer Manager, 1m FTE | BH1 - Staff Costs | Month | 1,00 | 4.142,00 | 4.142,00 |
| External collaboration with Network members | Researcher 3 m FTE | BH1 - Staff Costs | Month | 3,00 | 4.000,00 | 12.000,00 | 20.500,00 |

*Page 39/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Travel costs and related allowances for the mobility periods | BH2 - Travel Costs and Related Subsistence Allowances | Item | 2,00 | 1.500,00 | 3.000,00 |  |
| External  Collaborators service contract for experiments to be performed at ICGEB (2/3 months) | BH6 - Subcontracting Costs | Service | 1,00 | 5.500,00 | 5.500,00 |
| **Total estimated eligible direct costs (EUR)** | | | | | | | 1.236.329,00 |
| **BH7 - Indirect cost (15% of BH1+BH1A) (EUR)** | | | | | | | 102.579,00 |
| **Total estimated eligible project costs (EUR)** | | | | | | | 1.338.908,00 |

***5.2 Overview table WP/Output/Activity***

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **WP** | **WP total budget** | **Output** | **Output total budget** | **Activity** | **Activity total budget** |
| Management | 186.852,35 | Management outputs | 186.852,35 | Daily management and  liaison with the FO | 22.498,27 |
| PSC set-up, organisation of PSC meetings and  consortium technical updates | 27.804,88 |
| Co-organisation of international meetings on TBE | 21.280,00 |
| Participation in PSC meetings, consortium technical updates and other project meetings | 19.456,80 |
| Participation in PSC meetings, consortium technical updates and other project meetings | 33.600,00 |
| Co-organisation of international meetings on TBE | 8.000,00 |

*Page 40/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  | Participation in PSC meetings, consortium technical updates and other project meetings | 10.060,00 |
| Narrative and Financial reporting and Audits | 4.000,00 |
| Narrative and Financial reporting and Audits | 6.256,80 |
| Narrative and Financial reporting and Audits | 3.600,00 |
| Narrative and Financial reporting and Audits | 29.704,50 |
| Mid-term internal evaluation | 591,10 |
| Communication | 161.394,24 | Communication outputs | 161.394,24 | Development of communication plan -  Reopen | 7.078,97 |
| Identification of key stakeholders in PPs countries and in other countries in the target Region | 7.600,00 |
| Organisation of the launching event | 6.834,35 |
| Creation of project website and production of leaflets and other promotional materials | 2.500,00 |
| Preparation of web updates, posts on social media and six- month bulletins | 19.836,92 |

*Page 41/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

*Page 42/53*

|  |  |
| --- | --- |
| Scientific publications (OA) and presentations in scientific conferences such as the International Congress of Virology, Czechoslovak Conference of Virology, Ticks and Tick-borne Diseases meeting | 19.636,18 |
| Enhancement and Strenghtening of Social  Media Coverage and Visibility of the Project | 30.894,87 |
| Scientific publications (OA) and presentations of results in national and international scientific conferences such as ISTTBD in Weimar, Czechoslovak Virology Conference in Brno, and others | 14.513,60 |
| Scientific publications (OA) and presentations of results  in national and international scientific conferences such  as TTP10, JENA conference, Nor-Tick and SNÄFF | 10.800,00 |
| Scientific publications (OA) and presentations in international conferences (European Congress of Virology, Positive-Strand RNA Viruses Keystone Symposium, Gordon conference on cells and viruses) | 22.000,00 |

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  | Scientific publications (OA) and presentations in national and international conferences such as European Congress  of Virology, American Society of Virology, Gordon and Keystone meetings of Virology | 12.865,00 |
| TBFVnet closing event | 6.834,35 |
| Training and transfer of knowledge on surveillance at the regional level | 419.487,20 | Training on diagnostic assays  delivered | 315.260,20 | Preparation and exchange of research material and training  on TBEV NS1 based ELISA | 152.362,50 |
| One-week training at the ICGEB for Beneficiary partner VRI | 8.792,30 |
| One-week training at the ICGEB for Expertise partner NIPH | 1.750,00 |
| One-week training at the ICGEB for Beneficiary partner SAS | 1.350,00 |
| One-week training at the ICGEB for Donor State NIPH | 1.500,00 |
| Experiments at NIPH  (POWV, OHFV and LIV NS1 based ELISA) | 10.500,00 |
| One-month visit at ICGEB for tests validation (POWV, OHFV and LIV NS1 based ELISA) | 12.200,00 |
| Collection of ticks and measurements of climatic parameters | 15.000,00 |
| Test and evaluation of TBEV NS1 based ELISA | 3.000,00 |

*Page 43/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | Creation of a databank of TBFV sequences and availability of the same to the scientific community | 31.753,80 |
| Set up of diagnostics for TBEV | 73.051,60 |
| Test of new set of RT PCR primers for TBFV diagnosis | 4.000,00 |
| Scientific interaction between Donor and Beneficiary States facilitated | 104.227,00 | Preparation and sharing of diagnostic protocol for TBEV  RT PCR with standards and controls with all PPs and expanded network, and delivery of short term training sessions to Beneficiary Partners | 2.800,00 |
| Development of pipeline for direct sequencing of viral isolates and tested on the field | 27.750,00 |
| Short term training of staff at NIPH for RT PCR and sequencing for Beneficiary partner VRI | 27.961,50 |
| Short term training of staff at NIPH for RT PCR and sequencing for Beneficiary partner ICGEB | 20.800,00 |
| Short term training of staff at NIPH for RT PCR and sequencing for Beneficiary partner SAS | 1.350,00 |
| TBFVnet (first) regional seminar | 7.403,00 |
| TBFVnet (second) regional seminar | 8.162,50 |

*Page 44/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  | TBFVnet (third) regional seminar | 8.000,00 |
| Collaborative research for antiviral drug discovery | 571.174,66 | Cross-labs experiments for  antiviral drug discovery conducted | 571.174,66 | Exchange of junior staff (one month total time for each visit  for the duration of the activity) of VRI to SAS for the  definition of a common strategy on TBFV pathogenesis studies | 21.876,90 |
| Exchange of junior staff of ICGEB to SAS (1 month) & VRI (2 months) for the definition of a common strategy on TBFV pathogenesis studies and antiviral drug discovery | 13.200,00 |
| Exchange of junior staff (one month total time for each visit for the duration of the activity) of SAS to VRI for the  definition of a common strategy on TBFV pathogenesis studies | 7.950,00 |
| 2-month visit to ICGEB for  the definition of novel readout techniques with expertise partners | 7.600,00 |
| 6-month visit to MIMS for the definition of novel readout techniques with expertise partners | 19.376,90 |
| Development and implementation of novel imaging techniques | 152.209,50 |
| Set up of in vivo models for testing | 89.642,36 |

*Page 45/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  | Preparation for cross-labs experiments for testing of antiviral strategies on a model of tick bite infection | 110.571,20 |
| Exchange of junior staff of MIMS to VRI (one month total time for each visit for the duration of the activity) | 6.000,00 |
| Preliminary studies on TBFV pathogenesis and antiviral drug discovery | 113.787,00 |
| Definition of a general scheme for IP protection in the context of reagents exchange | 6.660,80 |
| External collaboration with Network members | 22.300,00 |

***5.3 Project co-financing***

*Please describe the consortium’s operational and financial capacity to provide the required co-financing.*

All PPs have operational and financial capacity to implement the project and to provide the required co-financing, which mainly refer to Staff costs and internal institutional resources. In particular:

- the LP VRI will secure institutional funding from the State Budget of the Czech Republic (via the Ministry of Agriculture)

- the CSFC will co-finance with staff salaries and/or supplies from own institutional (internal) funds

- the SAS will secure institutional funding of permanent staff

- the MIMS will secure own institutional funding

- the ICGEB will secure the core budget for salaries of involved staff

*Page 46/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | Veterinary  Research Institute | Czech Republic | Lead partner | University or  research institution | € 453.812,39 | % 90,00 | € 408.431,15 | € 45.381,24 | € 0,00 |
| 2 | Federal State  Autonomous Scientific Institution «Chumakov Federal Scientific Center for Research and Development of I mmune-and-  biological Products of Russian  Academy of Sciences» (Institute of Poliomyelitis) | Russia | Beneficiary  partner | University or research institution | € 0,00 | % 90,00 | € 0,00 | € 0,00 | € 0,00 |
| 3 | Biomedical  Research Center of the Slovak Academy of Sciences | Slovakia | Beneficiary  partner | University or research institution | € 293.380,00 | % 90,00 | € 264.042,00 | € 29.338,00 | € 0,00 |
| 4 | Norwegian  Institute of Public Health | Norway | Expertise partner | Public | € 133.903,00 | % 100,00 | € 133.903,00 | € 0,00 | € 0,00 |
| 5 | Umeå University | Sweden | Expertise partner | University or  research institution | € 0,00 | % 90,00 | € 0,00 | € 0,00 | € 0,00 |
| 6 | International  Centre for Genetic Engineering and Biotechnology - ICGEB | International | Expertise partner | International organisation | € 457.813,06 | % 85,00 | € 389.141,10 | € 68.671,96 | € 0,00 |

*Page 47/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |
| --- | --- |
| **Total estimated eligible project costs (in EUR)** | € 1.338.908,00 |
| **Maximum estimated project grant (in EUR)** | € 1.195.517,00 |
| **Total estimated project co-financing (in EUR)** | € 143.391,00 |

***5.4 Work package cost per budget headings***

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **BH1 - Staff Costs** | **BH1a - Voluntary**  **Work** | **BH2 - Travel** **Costs and** **Related** **Subsistence** **Allowances** | **BH3 -** **Consumables and** **Supplies** | **BH4 - Equipment** **Costs** | **BH5 - Project** **Contract** **Requirements** **Costs** | **BH6 -** **Subcontracting** **Costs** | **BH7 - Indirect** **Costs** |
| Management | 70.062,91 | 0,00 | 91.080,00 | 0,00 | 0,00 | 15.200,00 | 0,00 | 10.509,44 |
| Communication | 76.603,70 | 0,00 | 25.400,00 | 0,00 | 0,00 | 0,00 | 47.900,00 | 11.490,54 |
| Training and  transfer of knowledge on surveillance at the regional level | 202.508,00 0,00 40.150,00 126.050,00 0,00 0,00 20.403,00 30.376,20 |  |  |  |  |  |  |  |
| Collaborative research for antiviral drug discovery | 334.688,40 | 0,00 | 47.250,00 | 133.533,00 | 0,00 | 0,00 | 5.500,00 | 50.203,26 |

***5.5 Partners versus Budget headings***

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **BH1 - Staff Costs** | **BH1a - Voluntary**  **Work** | **BH2 - Travel** **Costs and** **Related** **Subsistence** **Allowances** | **BH3 -** **Consumables and** **Supplies** | **BH4 - Equipment** **Costs** | **BH5 - Project** **Contract** **Requirements** **Costs** | **BH6 -** **Subcontracting** **Costs** | **BH7 - Indirect** **Costs** |
| Veterinary Research Institute | 279.532,51 | 0,00 | 38.500,00 | 80.350,00 | 0,00 | 4.000,00 | 9.500,00 | 41.929,88 |

*Page 48/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Federal State Autonomous Scientific Institution «Chumakov  Federal Scientific Center for  Research and Development of Im mune-and-  biological Products of Russian  Academy of Sciences» (Institute of Poliomyelitis) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Biomedical Research Center of the Slovak  Academy of Sciences | 116.160,00 | 0,00 | 70.130,00 | 63.066,00 | 0,00 | 3.000,00 | 23.600,00 | 17.424,00 |
| Norwegian Institute of Public Health | 8.000,00 | 0,00 | 60.850,00 | 48.050,00 | 0,00 | 3.600,00 | 12.203,00 | 1.200,00 |
| Umeå University | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| International  Centre for Genetic  Engineering and  Biotechnology -  ICGEB | 280.170,50 0,00 34.400,00 68.117,00 0,00 4.600,00 28.500,00 42.025,56 |  |  |  |  |  |  |  |

***5.6 Work packages versus partners***

*Page 49/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Veterinary Research** **Institute** | **Federal State** **Autonomous Scientific** **Institution «Chumakov** **Federal Scientific** **Center for Research** **and Development of** **Immune-and-biological** **Products of Russian** **Academy of Sciences»** **(Institute of** **Poliomyelitis)** | **Biomedical Research** **Center of the Slovak** **Academy of Sciences** | **Norwegian Institute of** **Public Health** | **Umeå University** | **International Centre for**  **Genetic Engineering** **and Biotechnology -** **ICGEB** |
| Management | 62.894,25 | 0,00 | 46.993,60 | 37.200,00 | 0,00 | 39.764,50 |
| Communication | 33.304,88 | 0,00 | 36.513,60 | 10.800,00 | 0,00 | 80.775,76 |
| Training and transfer of  knowledge on surveillance at the regional level | 68.507,60 0,00 83.751,60 85.903,00 0,00 181.325,00 |  |  |  |  |  |
| Collaborative research for antiviral drug discovery | 289.105,66 | 0,00 | 126.121,20 | 0,00 | 0,00 | 155.947,80 |

***5.7 Summary of project budget per work packages, partners and budget headings***

|  |  |  |
| --- | --- | --- |
| **Work package title** | **Total estimated eligible costs per work package** | **Percent of total eligible costs** |
| Management | 186.852,35 | % 13,96 |
| Communication | 161.394,24 | % 12,05 |
| Training and transfer of knowledge on surveillance at the regional level | 419.487,20 % 31,33 |  |
| Collaborative research for antiviral drug discovery | 571.174,66 | % 42,66 |

|  |  |  |
| --- | --- | --- |
| **Partner name** | **Total estimated eligible costs per partner** | **Percent of total eligible costs** |
| Veterinary Research Institute | 453.812,39 | % 33,89 |

*Page 50/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |
| --- | --- | --- |
| Federal State Autonomous Scientific Institution «Chumakov Federal Scientific Center for Research and Development of Immune-and-biological Products of Russian Academy of  Sciences» (Institute of Poliomyelitis) | 0,00 | % 0,00 |
| Biomedical Research Center of the Slovak Academy of Sciences | 293.380,00 | % 21,91 |
| Norwegian Institute of Public Health | 133.903,00 | % 10,00 |
| Umeå University | 0,00 | % 0,00 |
| International Centre for Genetic Engineering and Biotechnology - ICGEB | 457.813,06 % 34,19 |  |

|  |  |  |
| --- | --- | --- |
| **Budget heading** | **Total estimated eligible costs per budget heading** | **Percent of total eligible costs** |
| BH1 - Staff Costs | 683.863,01 | % 51,08 |
| BH1a - Voluntary Work | 0,00 | % 0,00 |
| BH2 - Travel Costs and Related Subsistence Allowances | 203.880,00 | % 15,23 |
| BH3 - Consumables and Supplies | 259.583,00 | %19,39 |
| BH4 - Equipment Costs | 0,00 | % 0,00 |
| BH5 - Project Contract Requirements Costs | 15.200,00 | % 1,14 |
| BH6 - Subcontracting Costs | 73.803,00 | % 5,51 |
| BH7 - Indirect Costs | 102.579,44 | % 7,66 |

***5.8 Project costs in relation to outcomes***

*Please note that costs of the Management and Communication work packages is distributed (pro-rata) on all project outcomes.*

|  |  |  |
| --- | --- | --- |
| **Outcomes** | **Total estimated eligible costs (in EUR)** | **Percent of total eligible costs** |
| Enhanced performance of research institutions | 1.198.042,61 | % 89,48 |
| Enhanced cooperation and improved mutual knowledge and understanding between the donor and beneficiary states. | 140.865,84 % 10,52 |  |

***5.9 Work package cost per outcome***

*Please note that the costs of Management and Communication work packages is distributed pro-rata on all outcomes.*

*Page 51/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |
| --- | --- | --- |
|  | **Enhanced performance of research institutions** | **Enhanced cooperation and improved mutual knowledge**  **and understanding between the donor and beneficiary** **states.** |
| Management | 167.193,72 | 19.658,63 |
| Communication | 144.414,04 | 16.980,20 |
| Training and transfer of knowledge on surveillance at the regional level | 315.260,20 104.227,00 |  |
| Collaborative research for antiviral drug discovery | 571.174,66 | 0,00 |

***5.10 Budget forecast per implementation periods***

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Partner** | **Period 1** | **Period 2** | **Period 3** | **Period 4** | **Period 5** | **Period 6** | **Period 7** | **Period 8** | **Total** |
| 01 July 2020 - 31 December 2020 | 01 January 2021  - 30 June 2021 | 01 July 2021 - 31  December 2021 | 01 January 2022  - 30 June 2022 | 01 July 2022 - 31  December 2022 | 01 January 2023  - 30 June 2023 | 01 July 2023 - 31  December 2023 | 01 January 2024  - 31 January  2024 | 01 July 2020 - 31  January 2024 |
| Veterinary Research Institute | 17.542,86 | 31.707,91 | 35.910,54 | 38.080,00 | 37.700,00 | 98.556,61 | 96.712,17 | 97.602,30 | 453.812,39 |
| Federal State Autonomous Scientific Institution «Chumakov Federal Scientific Center for Research and Development of I mmune-and-  biological Products of Russian  Academy of Sciences» (Institute of Poliomyelitis) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |

*Page 52/53*

EEA and Norway Grants Fund for Regional Cooperation PROJECT DESCRIPTION

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Biomedical Research Center of the Slovak Academy of Sciences | 0,00 | 5.799,74 | 21.870,03 | 60.000,00 | 60.000,00 | 58.270,00 | 45.110,23 | 42.330,00 | 293.380,00 |
| Norwegian Institute of Public Health | 0,00 | 12.200,05 | 8.403,42 | 27.131,50 | 27.131,03 | 25.273,00 | 18.404,00 | 15.360,00 | 133.903,00 |
| Umeå University | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| International  Centre for  Genetic  Engineering and  Biotechnology -  ICGEB | 14.395,75 29.017,40 50.883,37 65.000,00 60.000,00 91.830,97 73.342,80 73.342,79 457.813,08 |  |  |  |  |  |  |  |  |
| **Total** | 31.938,61 | 78.725,10 | 117.067,36 | 190.211,50 | 184.831,03 | 273.930,58 | 233.569,20 | 228.635,09 | 1.338.908,00 |

***5.11 System of payments***

|  |  |
| --- | --- |
| **Advance payment** | No |
| **Reimbursement of costs incurred** | Yes |


***5.12 Revenue and state aid***

Is there any revenue foreseen in the project?

No

Are there any state aid implications related to the project? Any support under the Fund shall comply with the state aid rules. In case any project activity having potential impact on state aid mark YES and provide additional clarification in annex.

No



Signature Not Verified

Signature Not Verified

'

Dokument podpisan przez

*Page 53/53*

[Powered by TCPDF (www.tcpdf.org)](http://www.tcpdf.org/)